How antifungal play Amplyx plans to deploy series C
By Amran Gowani, Senior Editor, Research & Analytics | Aug 4, 2017 | 11:54 PM GMT
Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001.
On Aug. 2, the biotech
Read the full 312 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD